Scancell Holdings (GB:SCLP) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Scancell Holdings has released encouraging results from its SCOPE trial, showing an 80% progression-free survival rate at six months among advanced melanoma patients treated with its SCIB1 in combination with ipilimumab and nivolumab. The trial’s impressive disease control rate of 84% and an objective response rate of 72% suggest that Scancell’s approach offers a promising enhancement over standard double checkpoint therapies. As the trial progresses, these results could mark a significant advancement in first-line therapy for advanced melanoma, potentially boosting investor confidence in Scancell’s innovative immunotherapy solutions.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Super Micro Stock Soars 40% on Hiring New Auditor and Averting Delisting
- ‘Stay Away for Now,’ Says Top Investor About Palantir Stock
- ‘Too Late to Jump In,’ Says Ladenburg About SoundHound AI Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
